The Need Chronic lymphocytic leukemia (CLL) accounts for one quarter of new cases of leukemia. CLL is the most prevalent adult leukemia in Western countries and is characterized by a mature B-cell phenotype. Given the burden of this disease, a large pipeline of drugs for treatment are in progress…

This novel therapeutic approach leverages structural nanotechnology to create a DNA nanostructure that acts as a customizable delivery vehicle for therapeutic molecules. The technology allows for a highly tunable and customizable multi-functional drug delivery platform that incorporates interchang…

DHODH is a rate-limiting enzyme in de novo pyrimidine synthesis. Rapidly dividing cancer cells are therefore sensitive to blockade of this pathway. New research has shown DHODH inhibition can induce differentiation in acute myeloid leukemia (AML) cell lines, translating to increased survival in an…

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and the current therapies are not curative. High-risk genetic modifications are associated with poor response to traditional therapies. Flavopiridol, a broad-spectrum cyclin-dependent kinase inhibitor, activates significant clini…

The third leading cause of cancer death worldwide is hepatocellular carcinoma (HCC). Due to the rise in the incidence of hepatitis C virus infection, HCC is expected to increase in the United States. Many patients with HCC are not candidates for surgery because of the location or size of their tum…